Stocks · News reference

Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery Platform

Aug 24, 2026, 1:14 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 17, 2026, 9:06 PMBenzinga Insights
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out today.
Read original at benzinga
AMLX APUS DCGO GELS GNPX
SEC EDGARAug 17, 2026, 4:37 PMSEC EDGAR
8-K filing — Lexaria Bioscience Corp. (LEXX)
Filed: 2026-08-17 AccNo: 0001640334-26-001384 Size: 135 KB Item 8.01: Other Events
Read original at edgar
LEXX
BenzingaAug 13, 2026, 7:18 PMHenry Khederian
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know
Lexaria Bioscience shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio.
Read original at benzinga
LEXX